Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals (VRTX) Just Overtook the 20-Day Moving Average
Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average, which suggests a short-term bullish trend.
Vertex Pharmaceuticals (VRTX) Crossed Above the 50-Day Moving Average: What That Means for Investors
From a technical perspective, Vertex Pharmaceuticals (VRTX) is looking like an interesting pick, as it just reached a key level of support. VRTX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2024 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Dr. Reshma Kewalramani - President and CEO Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Jessica Fye - J.P. Morgan Salveen Richter - Goldman Sachs Chris Garcia - Morgan Stanley Mohit Bansal - Wells Fargo Tazeen Ahmad - Bank of America Michael Yee - Jefferies Evan Seigerman - BMO Capital Markets Phil Nadeau - TD Cowen Debjit Chattopadhyay - Guggenheim Partners Olivia Brayer - Cantor Fitzgerald Liisa Bayko - Evercore ISI Operator Good day.
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.
Prediction: Vertex Pharmaceuticals (VRTX) Could Be The Next Stock Split Stock
Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices.
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $475.08, representing a +1% change from its previous close.
Vertex (VRTX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top -and-bottom-line estimates for Vertex (VRTX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note
Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Smartest Growth Stock to Buy With $500 Right Now
This stock might not be available for under $500 for long.
